{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T02:09:50Z","timestamp":1791684590902,"version":"4.3.4"},"reference-count":60,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Autoimmunity Reviews"],"published-print":{"date-parts":[[2022,2]]},"DOI":"10.1016\/j.autrev.2021.102997","type":"journal-article","created":{"date-parts":[[2021,11,17]],"date-time":"2021-11-17T12:05:25Z","timestamp":1637150725000},"page":"102997","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":43,"title":["Efficacy and safety of intravenous and subcutaneous immunoglobulin therapy in idiopathic inflammatory myopathy: A systematic review and meta-analysis"],"prefix":"10.1016","volume":"21","author":[{"given":"Rudra Prosad","family":"Goswami","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soumendra Nath","family":"Haldar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moumita","family":"Chatterjee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pallavi","family":"Vij","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anneke J.","family":"van der Kooi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johan","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joost","family":"Raaphorst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danveer","family":"Bhadu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Gelardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Giovanna","family":"Danieli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uma","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.autrev.2021.102997_bb0005","article-title":"Intravenous immunoglobulins as first-line treatment in idiopathic inflammatory myopathies: a pilot study","author":"Lim","year":"2020","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.autrev.2021.102997_bb0010","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1007\/s10067-012-1940-5","article-title":"Intravenous immunoglobulin therapy in adult patients with polymyositis\/dermatomyositis: a systematic literature review","volume":"31","author":"Wang","year":"2012","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.autrev.2021.102997_bb0015","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1002\/art.37754","article-title":"Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: a randomized, placebo-phase trial","volume":"65","author":"Oddis","year":"2013","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2021.102997_bb0020","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1056\/NEJM199312303292704","article-title":"A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis","volume":"329","author":"Dalakas","year":"1993","journal-title":"N Engl J Med"},{"issue":"Suppl. 10","key":"10.1016\/j.autrev.2021.102997_bb0025","article-title":"Efficacy and safety of IVIg (Octagam 10%) in patients with active dermatomyositis. Results of a randomized, double-blind, placebo-controlled phase III trial (ProDERM study) [abstract]","volume":"72","author":"Aggarwal","year":"2020","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.autrev.2021.102997_bb0030","doi-asserted-by":"crossref","first-page":"114","DOI":"10.3899\/jrheum.190494","article-title":"Pilot study of the juvenile dermatomyositis consensus treatment plans: a CARRA registry study","volume":"48","author":"Liu","year":"2021","journal-title":"J Rheumatol"},{"key":"10.1016\/j.autrev.2021.102997_bb0035","article-title":"Intravenous immunoglobulin for inflammatory myositis: experience in a tertiary medical center","author":"Ohad","year":"2020","journal-title":"J Clin Rheumatol Pract Rep Rheum Musculoskelet Dis"},{"key":"10.1016\/j.autrev.2021.102997_bb0040","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.autrev.2010.09.004","article-title":"Subcutaneous immunoglobulin in polymyositis and dermatomyositis: a novel application","volume":"10","author":"Danieli","year":"2011","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2021.102997_bb0045","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1002\/acr.20035","article-title":"Validation of manual muscle testing and a subset of eight muscles for adult and juvenile idiopathic inflammatory myopathies","volume":"62","author":"Rider","year":"2010","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.autrev.2021.102997_bb0050","doi-asserted-by":"crossref","first-page":"665","DOI":"10.2340\/16501977-0235","article-title":"Reliability and validity of the Medical Research Council (MRC) scale and a modified scale for testing muscle strength in patients with radial palsy","volume":"40","author":"Paternostro-Sluga","year":"2008","journal-title":"J Rehabil Med"},{"key":"10.1016\/j.autrev.2021.102997_bb0055","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1056\/NEJM197502132920706","article-title":"Polymyositis and dermatomyositis (first of two parts)","volume":"292","author":"Bohan","year":"1975","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2021.102997_bb0060","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1056\/NEJM197502202920807","article-title":"Polymyositis and dermatomyositis (second of two parts)","volume":"292","author":"Bohan","year":"1975","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2021.102997_bb0065","doi-asserted-by":"crossref","first-page":"1884","DOI":"10.1093\/rheumatology\/kex226","article-title":"2016 ACR-EULAR adult dermatomyositis and polymyositis and juvenile dermatomyositis response criteria\u2014methodological aspects","volume":"56","author":"Rider","year":"2017","journal-title":"Rheumatology (Oxford)"},{"issue":"Suppl. 11","key":"10.1016\/j.autrev.2021.102997_bb0070","first-page":"S118","volume":"63","author":"Rider","year":"2011","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.autrev.2021.102997_bb0075","doi-asserted-by":"crossref","first-page":"1976","DOI":"10.1002\/art.1780401109","article-title":"Development of validated disease activity and damage indices for the juvenile idiopathic inflammatory myopathies: I. physician, parent, and patient global assessments. Juvenile dermatomyositis disease activity collaborative study group","volume":"40","author":"Rider","year":"1997","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2021.102997_bb0080","series-title":"Validity and inter-rater reliability testing of quality assessment instruments","author":"Hartling","year":"2012"},{"key":"10.1016\/j.autrev.2021.102997_bb0085","article-title":"Updated guidance for trusted systematic reviews: a new edition of the Cochrane handbook for systematic reviews of interventions","volume":"10","author":"Cumpston","year":"2019","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.autrev.2021.102997_bb0090","series-title":"Cochrane handbook for systematic reviews of interventions","year":"2021"},{"key":"10.1016\/j.autrev.2021.102997_bb0095","doi-asserted-by":"crossref","DOI":"10.1186\/1471-2288-14-45","article-title":"Newcastle-Ottawa scale: comparing reviewers\u2019 to authors\u2019 assessments","volume":"14","author":"Lo","year":"2014","journal-title":"BMC Med Res Methodol"},{"key":"10.1016\/j.autrev.2021.102997_bb0100","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/1471-2288-5-13","article-title":"Estimating the mean and variance from the median, range, and the size of a sample","volume":"5","author":"Hozo","year":"2005","journal-title":"BMC Med Res Methodol"},{"key":"10.1016\/j.autrev.2021.102997_bb0105","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"10.1016\/j.autrev.2021.102997_bb0110","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1002\/jrsm.11","article-title":"Outlier and influence diagnostics for meta-analysis","volume":"1","author":"Viechtbauer","year":"2010","journal-title":"Res Synth Methods"},{"key":"10.1016\/j.autrev.2021.102997_bb0115","doi-asserted-by":"crossref","first-page":"3443","DOI":"10.1002\/sim.2380","article-title":"A modified test for small-study effects in meta-analyses of controlled trials with binary endpoints","volume":"25","author":"Harbord","year":"2006","journal-title":"Stat Med"},{"key":"10.1016\/j.autrev.2021.102997_bb0120","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ"},{"key":"10.1016\/j.autrev.2021.102997_bb0125","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.cegh.2018.05.005","article-title":"Interpretation of subgroup analyses in systematic reviews: a tutorial","volume":"7","author":"Richardson","year":"2019","journal-title":"Clin Epidemiol Glob Health"},{"key":"10.1016\/j.autrev.2021.102997_bb0130","doi-asserted-by":"crossref","first-page":"e1000097","DOI":"10.1371\/journal.pmed.1000097","article-title":"PRISMA group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"6","author":"Moher","year":"2009","journal-title":"PLoS Med"},{"key":"10.1016\/j.autrev.2021.102997_bb0135","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.jpeds.2009.09.008","article-title":"Favorable outcome of juvenile dermatomyositis treated without systemic corticosteroids","volume":"156","author":"Levy","year":"2010","journal-title":"J Pediatr"},{"key":"10.1016\/j.autrev.2021.102997_bb0140","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1002\/acr.20325","article-title":"Intravenous immunoglobulins for steroid-refractory esophageal involvement related to polymyositis and dermatomyositis: a series of 73 patients","volume":"62","author":"Marie","year":"2010","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.autrev.2021.102997_bb0145","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1007\/s10067-013-2478-x","article-title":"Open-label study on treatment with 20% subcutaneous IgG administration in polymyositis and dermatomyositis","volume":"33","author":"Danieli","year":"2014","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.autrev.2021.102997_bb0150","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2019.102426","article-title":"Subcutaneous immunoglobulin in inflammatory myopathies: efficacy in different organ systems","volume":"19","author":"Danieli","year":"2020","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2021.102997_bb0155","doi-asserted-by":"crossref","first-page":"382","DOI":"10.3109\/s10165-011-0534-4","article-title":"Effects of intravenous immunoglobulin therapy in Japanese patients with polymyositis and dermatomyositis resistant to corticosteroids: a randomized double-blind placebo-controlled trial","volume":"22","author":"Miyasaka","year":"2012","journal-title":"Mod Rheumatol"},{"key":"10.1016\/j.autrev.2021.102997_bb0160","first-page":"397","article-title":"The effect of intravenous immunoglobulin (IVIG) treatment on patients with dermatomyositis: a 4-year follow-up study","volume":"30","author":"Kampylafka","year":"2012","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.autrev.2021.102997_bb0165","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1111\/jdv.12223","article-title":"Clinical efficacy of intravenous immunoglobulins for the treatment of dermatomyositis skin lesions without muscle disease","volume":"28","author":"Bounfour","year":"2014","journal-title":"J Eur Acad Dermatol Venereol JEADV"},{"key":"10.1016\/j.autrev.2021.102997_bb0170","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1016\/j.jaad.2013.06.007","article-title":"Intravenous immunoglobulin for refractory cutaneous dermatomyositis: a retrospective analysis from an academic medical center","volume":"69","author":"Femia","year":"2013","journal-title":"J Am Acad Dermatol"},{"issue":"Suppl. 10","key":"10.1016\/j.autrev.2021.102997_bb0175","first-page":"2021","article-title":"Use of long term subscutaneous immunoglobulins in inflammatory myopathies: a retrospective analysis of 19 patients [abstract]","volume":"67","author":"Cherin","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.autrev.2021.102997_bb0180","first-page":"S1","article-title":"Treatment with human immunoglobulin in patients with refractory inflammatory myopathy to rituximab [abstract]","volume":"25","author":"Charaja","year":"2019","journal-title":"JCR J Clin Rheumatol"},{"key":"10.1016\/j.autrev.2021.102997_bb0185","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.jaad.2015.03.047","article-title":"Intravenous immunoglobulin for treatment of dermatomyositis-associated dystrophic calcinosis","volume":"73","author":"Galimberti","year":"2015","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.autrev.2021.102997_bb0190","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1056\/NEJMc1506163","article-title":"Intravenous immune globulin for statin-triggered autoimmune myopathy","volume":"373","author":"Mammen","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2021.102997_bb0195","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1080\/00207454.2016.1204544","article-title":"High dose subcutaneous immunoglobulin for idiopathic inflammatory myopathies and dysimmune peripheral chronic neuropathies treatment: observational study of quality of life and tolerance","volume":"127","author":"Hachulla","year":"2017","journal-title":"Int J Neurosci"},{"key":"10.1016\/j.autrev.2021.102997_bb0200","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1111\/dmcn.13159","article-title":"IVIG in neurology study group. Intravenous immunoglobulin in paediatric neurology: safety, adherence to guidelines, and long-term outcome","volume":"58","author":"Nosadini","year":"2016","journal-title":"Dev Med Child Neurol"},{"key":"10.1016\/j.autrev.2021.102997_bb0205","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/s12969-016-0112-6","article-title":"Treatment with high-dose recombinant human hyaluronidase-facilitated subcutaneous immune globulins in patients with juvenile dermatomyositis who are intolerant to intravenous immune globulins: a report of 5 cases","volume":"14","author":"Speth","year":"2016","journal-title":"Pediatr Rheumatol Online J"},{"key":"10.1016\/j.autrev.2021.102997_bb0210","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1111\/imj.13308","article-title":"Use of intravenous immunoglobulin therapy for myositis: an audit in south Australian patients","volume":"47","author":"Foreman","year":"2017","journal-title":"Intern Med J"},{"key":"10.1016\/j.autrev.2021.102997_bb0215","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1136\/annrheumdis-2017-eular.5049","article-title":"FRI0400 efficacy of intravenous immunoglobulin therapy in refractory dysphagia in patients with idiopathic inflammatory myopathies","volume":"76","author":"Giannini","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2021.102997_bb0220","doi-asserted-by":"crossref","first-page":"S201","DOI":"10.1016\/j.jid.2017.07.147","article-title":"051 differences in the response of dermatologic symptoms and muscular strength after intravenous immunoglobulin therapy in dermatomyositis patients","volume":"137","author":"Wiala","year":"2017","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.autrev.2021.102997_bb0225","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1111\/ced.13607","article-title":"Intravenous immunoglobulin is an effective treatment for refractory cutaneous dermatomyositis","volume":"43","author":"Galimberti","year":"2018","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.autrev.2021.102997_bb0230","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1007\/s00296-019-04254-3","article-title":"Intravenous human immunoglobulin and\/or methylprednisolone pulse therapies as a possible treat-to-target strategy in immune-mediated necrotizing myopathies","volume":"39","author":"de Souza","year":"2019","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.autrev.2021.102997_bb0235","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s13075-019-2093-6","article-title":"Statin-induced anti-HMGCR myopathy: successful therapeutic strategies for corticosteroid-free remission in 55 patients","volume":"22","author":"Meyer","year":"2020","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.autrev.2021.102997_bb0240","doi-asserted-by":"crossref","DOI":"10.3390\/jcm9113454","article-title":"Efficacy and safety of high-dose immunoglobulin-based regimen in statin-associated autoimmune myopathy: a multi-center and multi-disciplinary retrospective study","volume":"9","author":"Treppo","year":"2020","journal-title":"J Clin Med"},{"key":"10.1016\/j.autrev.2021.102997_bb0245","article-title":"Long-term efficacy of adding intravenous immunoglobulins as treatment of refractory dysphagia related to myositis: a retrospective analysis","author":"Giannini","year":"2020","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.autrev.2021.102997_bb0250","doi-asserted-by":"crossref","first-page":"AB81","DOI":"10.1016\/j.jaad.2016.02.319","article-title":"Intravenous immunoglobulin for treatment of refractory cutaneous manifestations of dermatomyositis","volume":"74","author":"Li","year":"2016","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.autrev.2021.102997_bb0255","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000023677","article-title":"Prospective, double-blind, randomized, placebo-controlled phase III study evaluating efficacy and safety of octagam 10% in patients with dermatomyositis (\u201cProDERM study\u201d)","volume":"100","author":"Aggarwal","year":"2021","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.autrev.2021.102997_bb0260","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1001\/jama.1987.03400040111034","article-title":"Reversal of chronic polymyositis following intravenous immune serum globulin therapy","volume":"258","author":"Roifman","year":"1987","journal-title":"JAMA"},{"key":"10.1016\/j.autrev.2021.102997_bb0265","first-page":"1092","article-title":"Intravenous gamma globulin as first line therapy in polymyositis and dermatomyositis: an open study in 11 adult patients","volume":"21","author":"Cherin","year":"1994","journal-title":"J Rheumatol"},{"key":"10.1016\/j.autrev.2021.102997_bb0270","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/j.nmd.2010.03.011","article-title":"Oral dexamethasone pulse therapy versus daily prednisolone in sub-acute onset myositis, a randomised clinical trial","volume":"20","author":"van de Vlekkert","year":"2010","journal-title":"Neuromuscul Disord NMD"},{"key":"10.1016\/j.autrev.2021.102997_bb0275","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1038\/ncprheum0481","article-title":"Monoclonal antibody and intravenous immunoglobulin therapy for rheumatic diseases: rationale and mechanisms of action","volume":"3","author":"Bayry","year":"2007","journal-title":"Nat Clin Pract Rheumatol"},{"issue":"179","key":"10.1016\/j.autrev.2021.102997_bb0280","first-page":"5571","article-title":"Intravenous immunoglobulin therapy affects T regulatory cells by increasing their suppressive function","volume":"2007","author":"Kessel","year":"1950","journal-title":"J Immunol Baltim Md"},{"key":"10.1016\/j.autrev.2021.102997_bb0285","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1007\/s12016-011-8278-7","article-title":"Long-term therapy with intravenous immunoglobulin is beneficial in patients with autoimmune diseases","volume":"42","author":"Zandman-Goddard","year":"2012","journal-title":"Clin Rev Allergy Immunol"},{"key":"10.1016\/j.autrev.2021.102997_bb0290","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/j.autrev.2008.04.012","article-title":"What is the contents of the magic draft IVIg?","volume":"7","author":"Seite","year":"2008","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2021.102997_bb0295","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1111\/trf.14427","article-title":"Clinical indications for intravenous immunoglobulin utilization in a tertiary medical center: a 9-year retrospective study","volume":"58","author":"Shemer","year":"2018","journal-title":"Transfusion (Paris)"},{"key":"10.1016\/j.autrev.2021.102997_bb0300","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1177\/0961203317696589","article-title":"Intravenous immunoglobulin: a biological corticosteroid-sparing agent in some autoimmune conditions","volume":"26","author":"Watad","year":"2017","journal-title":"Lupus"}],"container-title":["Autoimmunity Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997221002779?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997221002779?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T21:23:12Z","timestamp":1761600192000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1568997221002779"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2]]},"references-count":60,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,2]]}},"alternative-id":["S1568997221002779"],"URL":"https:\/\/doi.org\/10.1016\/j.autrev.2021.102997","relation":{},"ISSN":["1568-9972"],"issn-type":[{"value":"1568-9972","type":"print"}],"subject":[],"published":{"date-parts":[[2022,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and safety of intravenous and subcutaneous immunoglobulin therapy in idiopathic inflammatory myopathy: A systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Autoimmunity Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.autrev.2021.102997","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"102997"}}